If used correctly, patient-reported outcomes can provide preliminary evidence of efficacy and tolerability from a patient perspective, as well as supporting regulatory review.
References
US Food and Drug Administration (FDA). The Drug Development Process–Step 3: Clinical Research; https://www.fda.gov/patients/drug-development-process/step-3-clinical-research (FDA, 2018).
Coleman, R. L. et al. Oncology 99, 444–453 (2021).
Basch, E. & Dueck, A. C. Exp. Opin. Drug Discov. 11, 753–758 (2016).
Fiteni, F. et al. BMC Cancer 19, 361 (2019).
Kirkham, J. J. et al. PLoS Med. 14, e1002447 (2017).
Calvert, M. et al. JAMA 319, 483–494 (2018).
Trotti, A. et al. Semin. Radiation Oncol. 13, 176–181 (2003).
Basch, E. et al. J. Natl Cancer Inst. 101, 1624–1632 (2009).
Kluetz, P. G. et al. Am. Soc. Clin. Oncol. Educ. Book 35, 67–73 (2016).
Chen, A. C., Mitchell, S. A., Minasian, L. M. & St. Germain, D. in Novel Designs of Early Phase Trials for Cancer Therapeutics (ed. Takimoto, K. A.) 193–208 (Elsevier, 2018).
Dueck, A. C. et al. JAMA Oncol. 1, 1051–1059 (2015).
Trask, P. C. et al. Clin. Trials 15, 616–623 (2018).
Shepshelovich, D. et al. Oncologist 24, e146–e148 (2019).
Pearman, T. P. et al. Cancer 124, 991–997 (2018).
FDA. Core Patient-Reported Outcomes in Cancer Clinical Trials: Draft Guidance for Industry (June 2020 draft); https://www.fda.gov/regulatory-information/search-fda-guidance-documents/core-patient-reported-outcomes-cancer-clinical-trials (FDA, 2021).
Chalasani, M., Vaidya, P. & Mullin, T. Res. Involve. Engagement 4, 10 (2018).
FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims (FDA, 2009).
Proceedings of Patient Reported Outcome Measures (PROMs) Conference Birmingham 2018. J. Patient Rep. Outcomes 2, 58 (2018).
UK Medicines and Healthcare Products Regulatory Agency. Innovative Licensing and Access Pathway https://www.gov.uk/guidance/innovative-licensing-and-access-pathway (accessed 13 December 2021).
Kluetz, P. G., O’Connor, D. J. & Soltys, K. Lancet Oncol. 19, e267–e274 (2018).
Kluetz, P. G. et al. Value Health 21, 742–747 (2018).
Tavridou, A. et al. Br. J. Clin. Pharmacol. 87, 2459–2464 (2021).
West, H. JAMA Oncol. 3, 423–423 (2017).
Acknowledgements
We thank A. Filer, P. Trivedi, D. Chanouzas, S. Ghosh and A. Dueck for their advice and suggestions during this project. The author(s) disclose receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Midlands-Wales Advanced Therapies Treatment Centre (MW-ATTC) program grant from Innovate UK to a consortium of partners including Health Technology Wales, the Welsh Blood Service and the University of Birmingham (grant number: IUK: 104232) and Innovate UK (part of UK Research and Innovation) grant Patient-reported outcomes assessment to support accelerated access to advanced cell and gene therapies: PROmics (grant number: 104777). The funder was not involved in any aspect of the research work. O.L.A., A.R. and M.C. receive funding from the NIHR Applied Research Collaboration, West Midlands (ARC), and the Brain Tumour Charity. O.L.A, receives funding from the NIHR Birmingham Biomedical Research Centre (BRC, West Midlands at the University of Birmingham) and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd. and Janssen Pharmaceuticals Inc. MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for Patient Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. She receives funding from the NIHR, UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and UK SPINE at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB, Gilead, Janssen and GSK Pharma. The views expressed in this article are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the MHRA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
O.L.A. declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck outside the submitted work. M.C. has received personal fees from Astellas, Aparito Ltd., CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Retzer, A., Aiyegbusi, O.L., Rowe, A. et al. The value of patient-reported outcomes in early-phase clinical trials. Nat Med 28, 18–20 (2022). https://doi.org/10.1038/s41591-021-01648-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01648-4
- Springer Nature America, Inc.